Oslo, Norway, 23 March 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors, today announces that its shares have been accepted to list on Oslo Børs, the main Oslo Stock Exchange. The Company was previously listed on Oslo Axess, a regulated and licensed market under the auspices of the Oslo Stock Exchange.
On 15 March 2017, the Board of Directors of Targovax ASA approved the financial statements for 2016 for issuance, subject to approval by the Annual General meeting on April 5, 2017.
Meltwater Newsfeed :
- 后石油经济时代挪威的创投生态 | 投资人说 March 21, 2017
- Derfor digger de Ullern videregående March 20, 2017
- Kreftbehandling: De nordiske landene kan gjøre noe resten av verden drømmer om | Ketil Widerberg - Aftenposten March 8, 2017
- 2/28/17 - PCI Biotech: Fourth quarter and preliminary 2016 results February 28, 2017